{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:20:18Z","timestamp":1790698818364,"version":"4.1.0"},"reference-count":24,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T00:00:00Z","timestamp":1561334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill & Melinda Gates Foundation","doi-asserted-by":"crossref","award":["GH 5342"],"award-info":[{"award-number":["GH 5342"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"DOI":"10.1371\/journal.pmed.1002839","type":"journal-article","created":{"date-parts":[[2019,6,24]],"date-time":"2019-06-24T23:21:37Z","timestamp":1561418497000},"page":"e1002839","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":85,"title":["The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6336-3824","authenticated-orcid":true,"given":"Gary J.","family":"Weil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8053-6603","authenticated-orcid":true,"given":"Joshua","family":"Bogus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0921-2443","authenticated-orcid":true,"given":"Michael","family":"Christian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Dubray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yenny","family":"Djuardi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4558-3417","authenticated-orcid":true,"given":"Peter U.","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2682-7316","authenticated-orcid":true,"given":"Charles W.","family":"Goss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myra","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Purushothaman","family":"Jambulingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3873-7860","authenticated-orcid":true,"given":"Christopher L.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijesh Sridhar","family":"Kuttiat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaliannagounder","family":"Krishnamoorthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0964-805X","authenticated-orcid":true,"given":"Moses","family":"Laman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Frantz","family":"Lemoine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katiuscia K.","family":"O\u2019Brian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9903-1023","authenticated-orcid":true,"given":"Leanne J.","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1288-5948","authenticated-orcid":true,"given":"Josaia","family":"Samuela","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth B.","family":"Schechtman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita","family":"Sircar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adinarayanan","family":"Srividya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew C.","family":"Steer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taniawati","family":"Supali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0804-0763","authenticated-orcid":true,"given":"Swaminathan","family":"Subramanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the DOLF IDA Safety Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,6,24]]},"reference":[{"issue":"9","key":"ref1","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1046\/j.1365-3156.2000.00620.x","article-title":"The global programme to eliminate lymphatic filariasis","volume":"5","author":"EA Ottesen","year":"2000","journal-title":"Trop Med Int Health"},{"key":"ref2","unstructured":"WHO. The Golbal Programme to Eliminate Lymphatic Filariasis: Progress Report 2000\u20132009 and Strategic Plan 2010\u20132020. Geneva: 2011."},{"issue":"11","key":"ref3","doi-asserted-by":"crossref","first-page":"e3333","DOI":"10.1371\/journal.pntd.0003333","article-title":"Assessing progress in reducing the at-risk population after 13 years of the global programme to eliminate lymphatic filariasis","volume":"8","author":"PJ Hooper","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"e3319","DOI":"10.1371\/journal.pntd.0003319","article-title":"Progress and impact of 13 years of the global programme to eliminate lymphatic filariasis on reducing the burden of filarial disease","volume":"8","author":"KD Ramaiah","year":"2014","journal-title":"PLoS Negl Trop Dis"},{"issue":"44","key":"ref5","first-page":"589","article-title":"Global programme to eliminate lymphatic filariasis: progress report, 2017","volume":"93","year":"2018","journal-title":"Wkly Epidemiol Rec"},{"issue":"6","key":"ref6","first-page":"491","article-title":"Strategies and tools for the control\/elimination of lymphatic filariasis","volume":"75","author":"EA Ottesen","year":"1997","journal-title":"Bull World Health Organ"},{"issue":"3","key":"ref7","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1093\/cid\/civ882","article-title":"Efficacy, Safety, and Pharmacokinetics of Coadministered Diethylcarbamazine, Albendazole, and Ivermectin for Treatment of Bancroftian Filariasis","volume":"62","author":"EK Thomsen","year":"2016","journal-title":"Clin Infect Dis"},{"key":"ref8","unstructured":"Ouattara AF, Kouadio O, Bjerum C, Koudou BJ, Meite A, Kazura JW, et al., editors. High efficacy of a single dose of co-administered ivermectin, diethylcarbamazine and albendazole in treatment of lymphatic filariasis in Cote d&apos;Ivoire. 65th Annual Meeting of the American Society of Tropical Medicine and Hygiene; 2016 Nov 13\u201317; Atlanta.Oakbrook Terrace, IL: American Society of Tropical Medicine and Hygiene; 2016."},{"issue":"19","key":"ref9","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1706854","article-title":"A trial of a triple drug treatment for lymphatic filariasis","volume":"379","author":"CL King","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/S1473-3099(16)30467-4","article-title":"Effectiveness of a triple-drug regimen for global elimination of lymphatic filariasis: a modelling study","volume":"17","author":"MA Irvine","year":"2017","journal-title":"Lancet Infect Dis"},{"issue":"5","key":"ref11","doi-asserted-by":"crossref","first-page":"e0006454","DOI":"10.1371\/journal.pntd.0006454","article-title":"Adverse events following single dose treatment of lymphatic filariasis: Observations from a review of the literature","volume":"12","author":"PJ Budge","year":"2018","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"ref12","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1093\/infdis\/jix578","article-title":"Changes in Cytokine, Filarial Antigen, and DNA Levels Associated With Adverse Events Following Treatment of Lymphatic Filariasis","volume":"217","author":"BJ Andersen","year":"2018","journal-title":"J Infect Dis"},{"key":"ref13","article-title":"2016 Code of Federal Regulations &amp; ICH Guidelines GCP Reference Guide","year":"2016"},{"key":"ref14","article-title":"Code of Fedreal Regulations, ICH Guidelines","year":"2016"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4269\/ajtmh.13-0089","article-title":"Laboratory and field evaluation of a new rapid test for detecting Wuchereria bancrofti antigen in human blood","volume":"89","author":"GJ Weil","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/s13071-015-0979-y","article-title":"A comparison of two tests for filarial antigenemia in areas in Sri Lanka and Indonesia with low-level persistence of lymphatic filariasis following mass drug administration","volume":"8","author":"TC Yahathugoda","year":"2015","journal-title":"Parasit Vectors"},{"key":"ref17","unstructured":"Services USDoHaH. Common terminology criteria for adverse events (CTCAE). 2009 [cited 2018 Jun 8]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf\" xlink:type=\"simple\">https:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf<\/ext-link>"},{"key":"ref18","unstructured":"Medical Dictionary for Regulatory Activities [cited 2017 Feb 3]. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.meddra.org\/\" xlink:type=\"simple\">https:\/\/www.meddra.org\/<\/ext-link>"},{"key":"ref19","article-title":"A practical handbook on the pharmacovigilance of medicines used in the treatment of tuberculosis","year":"2012"},{"key":"ref20","article-title":"SAS for mixed models","author":"RC Littel","year":"2006"},{"issue":"9","key":"ref21","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1111\/j.1365-3156.2008.02120.x","article-title":"Pharmacovigilance throught consumer feedback (reporting) in the mass treatment of lymphatic filariasis using diethylcarbamazine and albendazole in two districts of Sri Lanka","volume":"13","author":"S Gunawardena","year":"2008","journal-title":"Trop Med Int Health"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1590\/S0037-86822012000600017","article-title":"Adverse reactions followign mass drug administration with diethylcarbamazine in lymphatic filariasis endemic areas in the Northeast of Brazil","volume":"45","author":"AS Lima","year":"2012","journal-title":"Rev Soc Bras med Trop"},{"key":"ref23","unstructured":"WHO. Guideline: Alternative mass drug administration regimens to eliminate lymphatic filariasis. 2017. Contract No.: WHO\/HTM\/NTD\/PCT\/2017.07."},{"key":"ref24","unstructured":"Merck, Sharp &amp; Dohme. Program Expanded to Reach Additional 100 Million People Annually for Lymphatic Filariasis in Support of New, Evidence-Based WHO Guidelines. 2017. Available from: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/investors.merck.com\/news\/press-release-details\/2017\/Merck-Commemorates-30-Years-of-MECTIZAN-Donation-Program-Progress\/default.aspx\" xlink:type=\"simple\">http:\/\/investors.merck.com\/news\/press-release-details\/2017\/Merck-Commemorates-30-Years-of-MECTIZAN-Donation-Program-Progress\/default.aspx<\/ext-link>"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pmed.1002839","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T13:47:52Z","timestamp":1589032072000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1002839"}},"subtitle":[],"editor":[{"given":"Paul","family":"Garner","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,6,24]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,6,24]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1002839","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,24]]}}}